drug discovery Tag

Editorial Notice: This article describes laboratory research tools and is not medical advice. Findings from cell models do not by themselves show that a treatment is safe or effective in people. Products and suppliers mentioned in this article are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.

Understanding how the human immune system responds to infections, inflammation, and disease remains a major focus of medical research. However, studying immune cells directly can be challenging, particularly when researchers need consistent conditions across multiple experiments.

Laboratory cell models offer a practical solution, allowing scientists to investigate specific biological processes in controlled environments. Among these, THP-1 cells have become an established tool for studying immune cell behavior and the mechanisms involved in inflammatory responses.

[caption id="attachment_13764" align="alignleft" width="111"]MedicalResearch.com Interview with: Neel S. Madhukar Graduate student in the lab of Neel S. Madhukar[/caption] MedicalResearch.com Interview with: Neel S. Madhukar Graduate student in the lab of Olivier Elemento, PhD, Associate Professor Head, Laboratory of Cancer Systems Biology Department of Physiology and Biophysics Institute for Computational Biomedicine Weill Cornell Medical College Medical Research: What is the background for this study? What are the main findings? Response: It takes on average 2.6 billion dollars and 10-15 years to develop a single new drug. Despite massive investment in drug discovery by pharmaceutical companies, the number of drugs obtaining FDA approval each year has remained constant over the past decade. One of biggest bottlenecks in the process of developing a new drug is to understand precisely how a drug works, that is, what it binds to in cells, how it binds, and what it does when it is bound. This process is collectively called target identification and characterization of mechanisms of action. At present, target identification is a slow and failure-prone process, driven by laborious experimentation. Every time we seek to develop a new drug, such laborious experimentation needs to be redone from scratch. We are not learning from data acquired from our past successes and failures.